Mixed‐Genotype <scp>HCV</scp> Direct Acting Antiviral Outcomes: A <scp>CANUHC</scp> Analysis
The prevalence of mixed hepatitis C virus (HCV) genotype infection in a representative Canadian HCV cohort is reported and virological response with direct acting antiviral (DAA) treatment was evaluated. 3272 HCV-positive participants were enrolled, of which 2945 (90.0%) initiated DAA therapy. 0.8% were identified with mixed genotype infection. Overall sustained virological response (SVR) was 99.1% and did not differ based on mixed genotype status. Any historical disadvantage to achieving cure with HCV treatment in mixed genotype infection has been overcome by current DAA regimens.
Authors
- Sergio Borgia (ORCID: https://orcid.org/0000-0002-7816-2929)
- Curtis Cooper (ORCID: https://orcid.org/0000-0002-3368-3499)
- Gisela Macphail (ORCID: https://orcid.org/0000-0002-8576-5082)
- Daniel Smyth
- Alexander Wong (ORCID: https://orcid.org/0009-0009-9781-5479)
- Duncan Webster (ORCID: https://orcid.org/0000-0001-7692-7150)
- Hongqun Liu (ORCID: https://orcid.org/0000-0002-6805-5177)
- Marie‐Louise C. Vachon
- Haris Imsirovic (ORCID: https://orcid.org/0009-0008-1403-7070)
- Sam Lee (ORCID: https://orcid.org/0000-0002-6805-4051)
- Chris Fraser
- Jordan J. Feld
- Brian E. Conway
Institutions
- Dalhousie University (CA)
- University of Ottawa (CA)
- University of Calgary (CA)
- University of Toronto (CA)
- University of Victoria (CA)
- Ottawa Hospital (CA)
- University of Saskatchewan (CA)
- Vancouver Infectious Diseases Centre (CA)
- William Osler Health System (CA)
- Université Laval (CA)
- Ottawa Hospital Research Institute (CA)
- McMaster University (CA)
Publication Details
- Journal
- Journal of Viral Hepatitis
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1111/jvh.13995
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences
- Public Health Agency of Canada
- Public Health Agency